Tags

Type your tag names separated by a space and hit enter

Genitourinary syndrome of menopause (GSM) and laser VEL: a review.
Horm Mol Biol Clin Investig. 2019 Dec 19; 41(1)HM

Abstract

The purpose of this publication is to summarize the results of the vaginal erbium:yttrium-aluminum-garnet (Er:YAG) Smooth® laser (VEL) on the vaginal atrophy component of the genitourinary syndrome of menopause (GSM). GSM has two categories of clinical signs related to estrogen deficiency: symptoms of vulvovaginal atrophy (VVA) and urinary symptoms. This symptomatology is chronic, progressive over the years and affects a majority of women concerned by natural menopause but not exclusively: we must also consider the growing number of survivors of gynecological or non-gynecological cancers (breast, cervix, uterus, vagina, anus, etc.). At a time when hormonal treatment of menopause is contested as is the installation of under urethra prosthesis, the innovation provided by the VEL technology has the merit of offering the women concerned an effective therapeutic alternative with the security of a patent. The VEL technology has an original and unique process: acting only by thermal effect and not by ablation on tissue, VEL is a safe solution in terms of side effects and potential complications. Studies have been increasing since 2012 and all demonstrate a significant improvement in the GSM signs and symptoms, as well as an improved sexual life after VEL treatment. Double-blind, placebo-controlled, randomized studies are expected in order to ultimately confirm the safety and effectiveness of VEL.

Authors+Show Affiliations

Vela-France (Vaginal Erbium Laser Academy France), Paris, France.Vela-Italia (Vaginal Erbium Laser Academy Italia), Pisa, Italy.Vela-France (Vaginal Erbium Laser Academy France), Paris, France.Vela-France (Vaginal Erbium Laser Academy France), Paris, France.Vela-France (Vaginal Erbium Laser Academy France), Paris, France.Vela-France (Vaginal Erbium Laser Academy France), Paris, France.Vela-France (Vaginal Erbium Laser Academy France), Paris, France.Vela-France (Vaginal Erbium Laser Academy France), Paris, France.Vela-France (Vaginal Erbium Laser Academy France), Paris, France.Vela-Italia (Vaginal Erbium Laser Academy Italia), Pisa, Italy.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

31855563

Citation

Elia, David, et al. "Genitourinary Syndrome of Menopause (GSM) and Laser VEL: a Review." Hormone Molecular Biology and Clinical Investigation, vol. 41, no. 1, 2019.
Elia D, Gambacciani M, Berreni N, et al. Genitourinary syndrome of menopause (GSM) and laser VEL: a review. Horm Mol Biol Clin Investig. 2019;41(1).
Elia, D., Gambacciani, M., Berreni, N., Bohbot, J. M., Druckmann, R., Geoffrion, H., Haab, F., Heiss, N., Rygaloff, N., & Russo, E. (2019). Genitourinary syndrome of menopause (GSM) and laser VEL: a review. Hormone Molecular Biology and Clinical Investigation, 41(1). https://doi.org/10.1515/hmbci-2019-0024
Elia D, et al. Genitourinary Syndrome of Menopause (GSM) and Laser VEL: a Review. Horm Mol Biol Clin Investig. 2019 Dec 19;41(1) PubMed PMID: 31855563.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Genitourinary syndrome of menopause (GSM) and laser VEL: a review. AU - Elia,David, AU - Gambacciani,Marco, AU - Berreni,Nicolas, AU - Bohbot,Jean Marc, AU - Druckmann,René, AU - Geoffrion,Hugues, AU - Haab,François, AU - Heiss,Niko, AU - Rygaloff,Nicolas, AU - Russo,Eleonora, Y1 - 2019/12/19/ PY - 2019/05/31/received PY - 2019/10/24/accepted PY - 2019/12/20/pubmed PY - 2020/5/22/medline PY - 2019/12/20/entrez KW - collagen KW - dyspareunia KW - genitourinary syndrome of menopause KW - gynecological cancers KW - laser erbium Smooth® KW - menopause KW - vaginal atrophy JF - Hormone molecular biology and clinical investigation JO - Horm Mol Biol Clin Investig VL - 41 IS - 1 N2 - The purpose of this publication is to summarize the results of the vaginal erbium:yttrium-aluminum-garnet (Er:YAG) Smooth® laser (VEL) on the vaginal atrophy component of the genitourinary syndrome of menopause (GSM). GSM has two categories of clinical signs related to estrogen deficiency: symptoms of vulvovaginal atrophy (VVA) and urinary symptoms. This symptomatology is chronic, progressive over the years and affects a majority of women concerned by natural menopause but not exclusively: we must also consider the growing number of survivors of gynecological or non-gynecological cancers (breast, cervix, uterus, vagina, anus, etc.). At a time when hormonal treatment of menopause is contested as is the installation of under urethra prosthesis, the innovation provided by the VEL technology has the merit of offering the women concerned an effective therapeutic alternative with the security of a patent. The VEL technology has an original and unique process: acting only by thermal effect and not by ablation on tissue, VEL is a safe solution in terms of side effects and potential complications. Studies have been increasing since 2012 and all demonstrate a significant improvement in the GSM signs and symptoms, as well as an improved sexual life after VEL treatment. Double-blind, placebo-controlled, randomized studies are expected in order to ultimately confirm the safety and effectiveness of VEL. SN - 1868-1891 UR - https://www.unboundmedicine.com/medline/citation/31855563/Genitourinary_syndrome_of_menopause__GSM__and_laser_VEL:_a_review_ L2 - https://www.degruyter.com/document/doi/10.1515/hmbci-2019-0024 DB - PRIME DP - Unbound Medicine ER -